Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients

Overview

Journal Nutrients

Date 2018 Mar 24

PMID 29570617

Citations 14

Authors

Evertine Wesselink

Renate M Winkels

Harm van Baar

Anne J M R Geijsen

Moniek van Zutphen

Henk K van Halteren

Bibi M E Hansson

Sandra A Radema

Johannes H W de Wilt

Ellen Kampman

Dieuwertje E G Kok

Affiliations

Soon will be listed here.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe side-effect in colorectal cancer (CRC) patients. This study assessed the association between habitual dietary intake of magnesium or calcium and prevalence and severity of chronic CIPN in CRC patients receiving adjuvant chemotherapy. For this prospective cohort study, 196 CRC patients were considered. Magnesium and calcium intake was determined using a food frequency questionnaire at diagnosis, during and after chemotherapy. Chronic CIPN was assessed 12 months after diagnosis using the quality of life questionnaire CIPN20. Prevalence ratios were calculated to assess the association between magnesium or calcium intake and the prevalence of CIPN. Multivariable linear regression analysis was used to assess the association between magnesium or calcium intake and severity of CIPN. CIPN was reported by 160 (82%) patients. Magnesium intake during chemotherapy was statistically significantly associated with lower prevalence of CIPN (prevalence ratio (PR) 0.53, 95% confidence interval (CI) 0.32, 0.92). Furthermore, higher dietary intake of magnesium during (β -1.08, 95% CI -1.95, -0.22) and after chemotherapy (β -0.93, 95% CI -1.81, -0.06) was associated with less severe CIPN. No associations were found for calcium intake and the prevalence and severity of CIPN. To conclude, we observed an association between higher dietary magnesium intake and lower prevalence and severity of CIPN in CRC patients.

Citing Articles

Examination of the relationship between serum zinc levels and peripheral neuropathy induced by paclitaxel/carboplatin combination therapy in gynecological cancer patients.

Torii Y, Naito K, Takagi J, Yasue A, Tsukada K, Fujii T Fujita Med J. 2025; 11(1):11-19.

PMID: 39896227 PMC: 11782941. DOI: 10.20407/fmj.2024-013.

Magnesium Ion: A New Switch in Tumor Treatment.

Huang L, Lin R, Chen J, Qi Y, Lin L Biomedicines. 2024; 12(8).

PMID: 39200180 PMC: 11351748. DOI: 10.3390/biomedicines12081717.

Integrative Omics Uncovers Low Tumorous Magnesium Content as A Driver Factor of Colorectal Cancer.

Zhang R, Hu M, Liu Y, Li W, Xu Z, He S Genomics Proteomics Bioinformatics. 2024; 22(4).

PMID: 39052867 PMC: 11514849. DOI: 10.1093/gpbjnl/qzae053.

Nonlinear relationship between dietary calcium and magnesium intake and peripheral neuropathy in the general population of the United States.

Wu Z, Yang X, Ruan Z, Li L, Wu J, Wang B Front Nutr. 2023; 10:1217465.

PMID: 37789899 PMC: 10544963. DOI: 10.3389/fnut.2023.1217465.

Cohort profile: Biomarkers related to folate-dependent one-carbon metabolism in colorectal cancer recurrence and survival - the FOCUS Consortium.

Gigic B, van Roekel E, Holowatyj A, Brezina S, Geijsen A, Ulvik A BMJ Open. 2022; 12(12):e062930.

PMID: 36549742 PMC: 9772678. DOI: 10.1136/bmjopen-2022-062930.

References

Staff N, Grisold A, Grisold W, Windebank A . Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017; 81(6):772-781. PMC: 5656281. DOI: 10.1002/ana.24951. View

Laires M, Monteiro C, Bicho M . Role of cellular magnesium in health and human disease. Front Biosci. 2004; 9:262-76. DOI: 10.2741/1223. View

de Baaij J, Hoenderop J, Bindels R . Regulation of magnesium balance: lessons learned from human genetic disease. Clin Kidney J. 2015; 5(Suppl 1):i15-i24. PMC: 4455826. DOI: 10.1093/ndtplus/sfr164. View

Kono T, Mamiya N, Chisato N, Ebisawa Y, Yamazaki H, Watari J . Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med. 2009; 2011:418481. PMC: 3135601. DOI: 10.1093/ecam/nep200. View

Chay W, Tan S, Lo Y, Ong S, Ng H, Gao F . Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia Pac J Clin Oncol. 2010; 6(4):270-7. DOI: 10.1111/j.1743-7563.2010.01344.x. View

Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A . Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015; 33(35):4176-87. DOI: 10.1200/JCO.2015.63.4238. View

Mols F, van de Poll-Franse L, Vreugdenhil G, Beijers A, Kieffer J, Aaronson N . Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population. Eur J Cancer. 2016; 69:28-38. DOI: 10.1016/j.ejca.2016.09.020. View

Alberti P, Rossi E, Cornblath D, Merkies I, Postma T, Frigeni B . Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol. 2013; 25(1):257-64. PMC: 3868322. DOI: 10.1093/annonc/mdt409. View

Leurs L, Schouten L, Mons M, Goldbohm R, van den Brandt P . Relationship between tap water hardness, magnesium, and calcium concentration and mortality due to ischemic heart disease or stroke in The Netherlands. Environ Health Perspect. 2010; 118(3):414-20. PMC: 2854772. DOI: 10.1289/ehp.0900782. View

10.

Loprinzi C, Qin R, Dakhil S, Fehrenbacher L, Flynn K, Atherton P . Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2013; 32(10):997-1005. PMC: 3965262. DOI: 10.1200/JCO.2013.52.0536. View

11.

Bara M, Guiet-Bara A, Durlach J . Regulation of sodium and potassium pathways by magnesium in cell membranes. Magnes Res. 1993; 6(2):167-77. View

12.

Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H . Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol. 2010; 15(1):82-7. DOI: 10.1007/s10147-009-0015-3. View

13.

Miltenburg N, Boogerd W . Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014; 40(7):872-82. DOI: 10.1016/j.ctrv.2014.04.004. View

14.

Smith E, Barton D, Qin R, Steen P, Aaronson N, Loprinzi C . Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res. 2013; 22(10):2787-99. PMC: 4383166. DOI: 10.1007/s11136-013-0379-8. View

15.

Attal N, Bouhassira D, Gautron M, Vaillant J, Mitry E, Lepere C . Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009; 144(3):245-252. DOI: 10.1016/j.pain.2009.03.024. View

16.

Knijn N, Tol J, Koopman M, Werter M, Imholz A, Valster F . The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer. 2010; 47(3):369-74. DOI: 10.1016/j.ejca.2010.10.006. View

17.

Vincenzi B, Frezza A, Schiavon G, Spoto C, Silvestris N, Addeo R . Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer. 2012; 21(5):1313-9. DOI: 10.1007/s00520-012-1667-5. View

18.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

19.

Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A . Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004; 10(12 Pt 1):4055-61. DOI: 10.1158/1078-0432.CCR-03-0666. View

20.

Bewick V, Cheek L, Ball J . Statistics review 8: Qualitative data - tests of association. Crit Care. 2004; 8(1):46-53. PMC: 420070. DOI: 10.1186/cc2428. View